



Universiteit  
Leiden  
The Netherlands

## **The migraine triad: chronification, depression, and medication overuse**

Louter, M.A.

### **Citation**

Louter, M. A. (2018, January 30). *The migraine triad: chronification, depression, and medication overuse*. Retrieved from <https://hdl.handle.net/1887/61141>

Version: Not Applicable (or Unknown)

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/61141>

**Note:** To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The following handle holds various files of this Leiden University dissertation:  
<http://hdl.handle.net/1887/61141>

**Author:** Louter, M.A.


**Title:** The migraine triad: chronification, depression, and medication overuse

**Issue Date:** 2018-01-30

# 4

CHAPTER

## Prevalence of lifetime depression in a large hemiplegic migraine cohort



M.A. Louter\*  
N. Pelzer\*  
I. de Boer  
E.C. Kuijvenhoven  
W.P.J. van Oosterhout  
E.W. van Zwet  
M.D. Ferrari  
G.M. Terwindt

*Neurology* 2016 Nov 29;87(22):2370-74

*\* both authors contributed equally to this manuscript*

## **Abstract**

### ***Objectives***

The aim of this study was to determine the prevalence of depression and determinants associated with depression in a large population of Hemiplegic Migraine (HM) patients.

### ***Methods***

We conducted a cross-sectional, validated questionnaire study among 89 well-defined HM patients and 235 headache-free controls. The prevalence of lifetime depression, and its relation to migraine characteristics was assessed.

### ***Results***

HM patients had increased odds for lifetime depression (OR 3.73, 95% CI 2.18-6.38) compared with controls. Use of acute anti-migraine medication was associated with lifetime depression.

### ***Conclusion***

Depression is part of the monogenic hemiplegic migraine phenotype. Further studies are needed to elucidate the pathophysiological role of HM genes in comorbid depression. For now, clinicians should take comorbid depression into consideration when starting prophylactic treatment of HM.

## Introduction

Hemiplegic Migraine (HM) is a rare autosomal dominantly inherited migraine subtype, characterized by motor weakness during the aura phase. (1) Three genes (*CACNA1A*, *ATP1A2* and *SCN1A*) have so far been associated with HM. Involvement of a fourth gene (*PRRT2*) in HM has been proposed, but further evidence is needed to support this claim. (2) HM is divided into two subtypes: Familial Hemiplegic Migraine (FHM), in which at least one first or second degree relative has HM, and Sporadic Hemiplegic Migraine (SHM), in which no first or second degree relative is affected.

The relationship between the common types of migraine and depression has been thoroughly investigated to identify shared aetiological factors. Bidirectional associations have been proven, suggesting shared genetic risk factors. (3, 4) As a monogenic migraine subtype, HM constitutes a more homogeneous model to study migraine pathophysiology than migraine subtypes with a complex genetic background (such as migraine with and without aura). In HM, prevalence of depression has only been studied on a very small scale. (5) It has been hypothesized that the core pathophysiological mechanisms are similar for HM and other types of migraine, with HM representing the severe end of the phenotypic migraine spectrum. If there is a direct relationship between migraine and depression, one could hypothesize that HM, as a more severe migraine phenotype, may be associated with at least an equal prevalence of depression compared to patients with common migraine subtypes. Even more, an increased prevalence of depression in HM may suggest an involvement of ion channels that are mutated in HM in the pathophysiology of (certain subtypes of) depression.

In this study, we studied the prevalence of lifetime depression in HM and the clinical determinants associated with depression in a unique large population of HM patients.

## Methods

### *Participants*

HM patients of Dutch origin were recruited from the HM research database of the Leiden University Medical Center including patients who visited our outpatient headache clinic or were interviewed by an experienced research-physician (NP) or neurologist (GMT). Patients were ineligible to participate, when aged <18 years, or when unable to fill in the questionnaires (e.g. due to mental retardation or cognitive decline). Healthy individuals willing to participate had to pass a screening and additional questionnaire online via the research website of the Leiden University

Migraine Neuro-Analysis program (LUMINA). (6) If participants did not report any symptoms of migraine, cluster headache, chronic tension type headache or medication overuse headache, they were considered as 'non-headache' healthy controls. These healthy controls were also sent web-based questionnaires on symptoms of (lifetime) depression and demographic characteristics identical to the questionnaires that were sent to the HM patients.

### *Standard Protocol Approvals, Registrations, and Patient Consents*

The study was approved by the medical ethics committee of Leiden University Medical Center and all participants provided informed consent.

### *Measurements*

Symptoms of depression were determined using validated cut-off scores for the Hospital Anxiety and Depression Scale (HADS) and the Center for Epidemiological Studies Depression Scale (CES-D). (7, 8) The HADS questionnaire is been used in clinical studies as it intrinsically corrects for the overlap between symptoms of somatic diseases and depression (e.g. lack of sleep, changes in appetite). Lifetime depression was defined as HADS-D  $\geq 8$ , or CES-D  $\geq 16$ , or a (past) depression diagnosed by a physician or (past) use of antidepressants for depression. The combination of current depression questionnaires and lifetime depression questions allowed for analyses on both lifetime and current depression. Current depression was defined as HADS-D  $\geq 8$ , and current anxiety was defined as HADS-A  $\geq 8$ . Information about headache frequency and anti-migraine medication use was collected via an additional questionnaire. Healthy controls were sent the same depression questionnaires as the HM patients.

### *Data analysis*

General characteristics were reported as medians (and interquartile range) or percentages. To take into account that some of the HM patients were family-related (originating from 18 separate families) we used a Generalized Estimating Equations (GEE) regression which can correct for this confounding. GEE was applied to study the prevalence of depression corrected for sex, age and the presence of related individuals. GEE regression was also used in the analysis of determinants associated with depression in HM patients. A  $p$ -value of  $<0.05$  was considered statistically significant. All analyses were performed with SPSS 20.0 (SPSS inc., IBM, USA).

## Results

### *Study population*

We included 89 participants with HM and 235 healthy controls in the study (figure 1). From 132 HM participants in the database, 20 were ineligible because of previously stated unwillingness to participate in further research ( $n=1$ ) or outdated contact information ( $n=19$ ), and 23 decided not to participate (19 familial HM, 4 sporadic HM). No differences were observed between participants ( $n=89$ ) and non-participants ( $n=43$ ) in age or sex. Differences in headache frequency and medication use between participants and non-participants could not be tested because of missing data in the non-participants. Information on genetic status was missing for three patients, and in ten patients genetic screening was incomplete.

### *Comparing HM patients with controls*

The prevalence of lifetime depression was 51.7% in HM patients compared to 21.3% in controls (table 1). In multivariate analysis, with correction for sex and for the fact that multiple participants belonged to shared families, a strong association with lifetime depression was established (table 2).

### *Comparing HM patients with and without lifetime depression*

HM patients affected by lifetime depression did not differ from patients without lifetime depression in sex, age, HM type, or mutation status (table 3). Migraine attack frequency tended to be higher in the depression group. Use of acute anti-migraine medication (also when analysed separately for analgesics and triptans) was increased in patients with depression. Lastly, current anxiety appeared highly comorbid with depression.

## Discussion

Here we studied the prevalence of life time depression in hemiplegic migraine (HM), a rare monogenic subtype of migraine. We found, like in the common types of migraine, a four time increased odds compared with controls.

In a previous study, using the same methodology and questionnaires to diagnose depression, we found a comparable prevalence of 45% for lifetime depression in the common types of migraine. (9) Migraine attacks with typical aura (without weakness) frequently occur in HM patients. (10) Therefore, the comorbidity of HM with depression could, at least partly, be due to presence of common types of migraine in our HM patients. Unfortunately, elaborate migraine characteristics

were not included in the questionnaires used in this study. It would, however, have been difficult to exclude common types of migraine, as the included HM patients may still develop such attacks. We therefore cannot provide exact figures on the prevalence of the common types of migraine in our population.

Depression in common migraine is strongly associated with migraine attack frequency and is a risk factor for chronification. (9) Due to the small number of HM patients we could not show an association with attack frequency. However, use of acute anti-migraine medication (simple analgesics and triptans) was associated with depression. Considering increased use of acute anti-migraine medication as a proxy for migraine severity, the association may not be dependent on attack frequency, but on the severity of accompanying migraine symptoms.

The lifetime prevalence of depression of 21% in the control population corresponds to published prevalence rates for depression (11), indicating that our measurement of lifetime depression appears accurate. HM patients showed increased anxiety which might have contributed to the increased comorbid prevalence of depression. Unravelling the exact role of anxiety should be a topic for future research. A possible limitation of the study is the fact that some of the patients are related to other individuals in the study, because HM families were included. However, it turned out that many different families participated, but each only contributed a few individuals (supplementary table 1). Furthermore, we performed a Generalized Estimating Equations analysis to correct for this possible bias. It should be noted that we did multiple statistical tests but kept the level of significance at 0.05, as is consistent with an exploratory study.

Although recent molecular genetic advances have provided insights into pathophysiological mechanisms of inherited channelopathies such as HM so far no relationship with depression have been shown or investigated. Extensive biophysical characterisation in representative model systems will be required to determine the contribution of different ion channel variants to the common types of migraine in general and the comorbidity with depression. (12)

Because of the cross-sectional design of our study, we can only speculate on the mechanism of action of the comorbidity between HM and depression. Our results may indicate that the genes involved in HM may, directly or indirectly, make patients more susceptible to depression. It would be interesting to study the role of ion channels encoded by *CACNA1A*, *ATP1A2* and *SCN1A* in large cohorts with comorbid depression and common forms of migraine. The high prevalence of depression in our HM cohort also may have clinical implications. HM patients should be screened for depression, and migraine prophylactics such as flunarizine or topiramate which may provoke depressive symptoms should perhaps be prescribed with caution in HM patients with active depression. (13)

Depression is part of the monogenic hemiplegic migraine phenotype. This increased risk of depression in HM patients should receive more attention in clinical practice, especially with regard to the choice of prophylactic anti-migraine medication. In addition, further studies are needed to elucidate the pathophysiological role of HM genes in comorbid migraine and depression.

## Figures and tables




Table 1. Sociodemographic and clinical characteristics. Comparison of of HM participants and controls.

|                                     | HM participants n=89 | Controls n=235  |
|-------------------------------------|----------------------|-----------------|
| Female sex (n (%))                  | 66 (74.2)            | 138 (58.7)      |
| Median age in years (IQR) (range)   | 46 (24) (20-70)      | 48 (24) (19-77) |
| HM type FHM (n (%))                 | 65 (73.0)            | -               |
| HADS-A median (IQR) (range)         | 5 (6) (0-17)         | 3 (3) (0-17)    |
| HADS-D median (IQR) (range)         | 4 (5) (0-12)         | 2 (3) (0-16)    |
| CES-D median (IQR) (range)          | 11 (15) (0-55)       | 4 (7) (0-41)    |
| Lifetime depression present (n (%)) | 46 (51.7)            | 50 (21.3)       |
| Current depression present (n (%))  | 36 (40.4)            | 29 (12.3)       |
| Current anxiety present (n (%))     | 32 (36.0)            | 24 (10.2)       |

Current depression: HADS-D  $\geq 8$ . Current anxiety: HADS-A  $\geq 8$ .

Table 2: GEE regression with odds of lifetime depression<sup>1</sup>

|                          | Univariate<br>OR | 95% CI    | P value | Multivariate<br>OR | 95% CI    | P value |
|--------------------------|------------------|-----------|---------|--------------------|-----------|---------|
| Presence of HM           | 4.04             | 2.38-6.88 | <0.001  | 3.73               | 2.18-6.38 | <0.001  |
| Sex<br>( female v. male) | 2.18             | 1.28-3.70 | 0.004   | 1.90               | 1.09-3.30 | 0.023   |
| Age                      | 0.99             | 0.97-1.01 | 0.19    | -                  | -         | -       |

<sup>1</sup>Corrected for multiple individuals from the same family.

Table 3: Comparison of HM participants with and without lifetime depression

|                                               | HM without<br>lifetime<br>depression n=43 | HM with<br>lifetime<br>depression n=46 | Univariate<br>OR | 95% CI    | P<br>value <sup>1</sup> |
|-----------------------------------------------|-------------------------------------------|----------------------------------------|------------------|-----------|-------------------------|
| Sex female (n (%)) (female v. male)           | 32 (74.4)                                 | 34 (73.9)                              | 0.97             | 0.40-2.37 | 0.95                    |
| Median Age (IQR) (range)                      | 48.0 (25) (22-70)                         | 44.5 (24) (23-69)                      | 1.0              | 0.95-1.03 | 0.61                    |
| Migraine attack frequency <sup>2,6</sup>      |                                           |                                        | -                | -         | 0.23 <sup>5</sup>       |
| Over one year ago (n (%))                     | 15 (38.5)                                 | 6 (14.3)                               | -                | -         | R                       |
| 1-2 attacks per year (n (%))                  | 14 (35.9)                                 | 17 (40.5)                              | -                | -         | -                       |
| 3-6 attacks per year (n (%))                  | 4 (10.3)                                  | 8 (19.0)                               | -                | -         | -                       |
| 7-12 attacks per year (n (%))                 | 3 (7.7)                                   | 6 (14.3)                               | -                | -         | -                       |
| 13-54 attacks per year (n (%))                | 1 (2.6)                                   | 4 (9.5)                                | -                | -         | -                       |
| > 54 per year (n (%))                         | 2 (5.1)                                   | 1 (2.4)                                | -                | -         | -                       |
| Use of acute medication <sup>2,3</sup>        |                                           |                                        | -                | -         | 0.008                   |
| No (n (%))                                    | 23 (59.0)                                 | 11 (26.2)                              | -                | -         | R                       |
| Yes, only when attack starts (n (%))          | 13 (33.3)                                 | 25 (59.5)                              | 4.10             | 1.69-9.98 | 0.002                   |
| Yes, (almost) daily (n (%))                   | 3 (7.7)                                   | 6 (14.3)                               | 2.39             | 0.54-10.7 | 0.25                    |
| Use of standard analgesics <sup>3</sup>       |                                           |                                        |                  |           |                         |
| Yes (n (%)) (R = No)                          | 19 (48.7)                                 | 32 (76.2)                              | 3.42             | 1.55-7.54 | 0.002                   |
| Median days per month (IQR)                   | 1.00 (8)                                  | 6.50 (10)                              | 1.05             | 0.98-1.12 | 0.19                    |
| Use of triptans <sup>2,3</sup>                |                                           |                                        |                  |           |                         |
| Yes (n (%)) (R = No)                          | 7 (17.9)                                  | 17 (40.5)                              | 3.15             | 1.32-7.52 | 0.01                    |
| Median days per month (IQR)                   | 0.00 (0)                                  | 0.00 (2)                               | 1.36             | 0.89-2.08 | 0.16                    |
| Use of prophylactic medication <sup>2,3</sup> |                                           |                                        |                  |           |                         |
| Yes (n (%)) (R = No)                          | 14 (35.9)                                 | 14 (33.3)                              | 0.88             | 0.32-2.45 | 0.81                    |
| HM type FHM (n (%)) (R = SHM)                 | 32 (74.4)                                 | 33 (71.7)                              | 0.90             | 0.29-2.81 | 0.78                    |
| Mutation status <sup>4</sup>                  |                                           |                                        | -                | -         | 0.53                    |
| No mutation found (n (%))                     | 19 (48.7)                                 | 22 (59.5)                              | -                | -         | R                       |
| CACNA1A mutation (n (%))                      | 9 (23.1)                                  | 7 (18.9)                               | -                | -         | -                       |
| ATP1A2 mutation (n (%))                       | 11 (28.2)                                 | 8 (21.6)                               | -                | -         | -                       |
| SCN1A mutation (n (%))                        | 0 (0)                                     | 0 (0)                                  | -                | -         | -                       |
| Current anxiety present (n (%)) (R = No)      | 4 (9.3)                                   | 28 (60.9)                              | 17.5             | 5.34-57.4 | < 0.001                 |

HM type FHM: number of patients that were familial HM cases (and not sporadic).

R, reference category in GEE. <sup>1</sup> Corrected for multiple individuals from the same family. <sup>2</sup> without lifetime depression n=39 and lifetime depression n= 42 (due to missing data). <sup>3</sup> questions specifically stated analgesics for severe headache. <sup>4</sup> no life time depression group n=39 and lifetime depression group n= 37 (due to missing data). <sup>5</sup> GEE regression performed with category 13-54 attacks per year and > 54 per year merged because of small numbers. The Fisher's exact test using all categories gave a p value of 0.13.

## References

1. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013;33(9):629-808.
2. Pelzer N, de Vries B, Kamphorst JT, Vijfhuizen LS, Ferrari MD, Haan J, et al. PRRT2 and hemiplegic migraine: a complex association. Neurology. 2014;83(3):288-90.
3. Stam AH, de Vries B, Janssens AC, Vanmolkot KR, Aulchenko YS, Henneman P, et al. Shared genetic factors in migraine and depression: evidence from a genetic isolate. Neurology. 2010;74(4):288-94.
4. Breslau N, Lipton RB, Stewart WF, Schultz LR, Welch KM. Comorbidity of migraine and depression: investigating potential etiology and prognosis. Neurology. 2003;60(8):1308-12.
5. Karner E, Delazer M, Benke T, Bosch S. Cognitive functions, emotional behavior, and quality of life in familial hemiplegic migraine. Cogn Behav Neurol. 2010;23(2):106-11.
6. van Oosterhout WP, Weller CM, Stam AH, Bakels F, Stijnen T, Ferrari MD, et al. Validation of the web-based LUMINA questionnaire for recruiting large cohorts of migraineurs. Cephalalgia. 2011;31(13):1359-67.
7. Bjelland I, Dahl AA, Haug TT, Neckelmann D. The validity of the Hospital Anxiety and Depression Scale. An updated literature review. JPsychosomRes. 2002;52(2):69-77.
8. Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Applied Psychological measurement. 1977;1:385-401.
9. Louter MA, Bosker JE, van Oosterhout WPJ, van Zwet EW, Zitman FG, Ferrari MD, et al. Cutaneous allodynia as a predictor of migraine chronification. Brain. 2013;136:3489-96.
10. Thomsen LL, Olesen J, Russell MB. Increased risk of migraine with typical aura in probands with familial hemiplegic migraine and their relatives. Eur J Neurol. 2003;10(4):421-7.
11. Bijl RV, Ravelli A, van ZG. Prevalence of psychiatric disorder in the general population: results of The Netherlands Mental Health Survey and Incidence Study (NEMESIS). SocPsychiatry PsychiatrEpidemiol. 1998;33(12):587-95.
12. Spillane J, Kullmann DM, Hanna MG. Genetic neurological channelopathies: molecular genetics and clinical phenotypes. J Neurol Neurosurg Psychiatry. 2016;87(1):37-48.
13. Celano CM, Freudenreich O, Fernandez-Robles C, Stern TA, Caro MA, Huffman JC. Depressogenic effects of medications: a review. Dialogues in clinical neuroscience. 2011;13(1):109-25.



